6 recruiting, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 6, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Recruiting 2, Unknown 1 |
Follow Relapse Multiple Myeloma: new trials by email Literature Review of Relapse Multiple Myeloma trials Research Report on Relapse Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) Talquetamab, Belantamab mafodotin, Pomalidomide - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Montefiore Medical Center | 50 | 2026-09-01 | 2026-07-22 |
| FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose) - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2026-08-05 | 2026-11-04 |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM DC/MM Fusion Vaccine, GM-CSF - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2026-01-30 | 2026-05-08 |
| Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma Talquetamab, Ciltacabtagene Autoleucel - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 31 | 2025-12-02 | 2026-01-05 |
| A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2025-01-31 | 2026-05-07 |
| A Study of MCARH109 and MCARH125 in People With Multiple Myeloma MCARH125, MCARH109 - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 15 | 2022-06-20 | 2026-07-06 |
| Descartes-25 in Relapsed/Refractory Multiple Myeloma Descartes-25 - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 9 | 2021-11-25 | 2024-11-12 |
| Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma CAR-BCMA - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Sheba Medical Center | 75 | 2021-09-19 | 2024-01-31 |
| B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma BCMA CAR-T cells - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 10 | 2021-07-01 | 2021-12-09 |
| INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma Pomalidomide, Dexamethasone, INCB053914 50 mg bis in die (BID) - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Withdrawn | Medical College of Wisconsin | 2021-07-01 | 2020-08-19 | |
| A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma OPD5 - Relapse Multiple Myeloma, Multiple Myeloma | Phase 1 | Withdrawn | Oncopeptides AB | 2021-05-27 | 2021-11-26 |
Multiple Myeloma (12) · Neoplasm, Residual (1) · Neoplasms, Plasma Cell (1)
Blood Protein Disorders (12) · Cardiovascular Diseases (12) · Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Hemorrhagic Disorders (12) · Hemostatic Disorders (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Paraproteinemias (12) · Vascular Diseases (12) · Neoplasms, Plasma Cell (11) · Neoplastic Processes (1)
Dexamethasone (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · pomalidomide (2) · talquetamab (2) · BID protein, human (1) · Calcium Dobesilate (1) · belantamab mafodotin (1) · carfilzomib (1) · daratumumab (1) · isatuximab (1) · selinexor (1)
Medical College of Wisconsin (3) · David Avigan (2) · Cartesian Therapeutics (1) · Memorial Sloan Kettering Cancer Center (1) · Montefiore Medical Center (1) · Natalie Callander (1) · Oncopeptides AB (1) · Sheba Medical Center (1) · Shenzhen University General Hospital (1)
United States (7) · China (1) · Czechia (1) · Israel (1) · Turkey (Türkiye) (1)
Binod Dhakal, MD (2) · David Avigan, MD (1) · David R Levitz, MD (1) · Jacalyn Rosenblatt, MD (1) · Li Yu (1) · Natalie Callander, MD (1) · Othman Akhtar, MBBS (1) · Sergio Giralt, MD (1) · Sham Mailankody, MBBS (1)